

LOS ALCÁZARES

ADVANCED THERAPIES SCIENTIFIC BASIS AND CLINICAL USE

19TH EDITION

July 2-4, 2025

*Directors:
Dr. José María Moraleda
Dr. Robert Sackstein*



PARA MÁS INFORMACIÓN



UNIVERSIDAD
DE MURCIA



Escuela
de Formación
Continua

CURSOS DE EXTENSIÓN UNIVERSITARIA Y ESCUELAS DE VERANO 2025



UNIVERSIDAD
DE MURCIA



Escuela
de Formación
Continua

ESCUELA DE FORMACIÓN CONTINUA

Edificio Luis Vives, Anexo,
Campus de Espinardo

✉ cursosdeextension@um.es

✉ @extensionumu

f extensionumu

📷 extensionumu

🌐 www.um.es/web/cursosdeextension



Instituto de Salud Carlos III (ISCIII) - RICORS/TERAV.
Proyecto: RD21/001.7/0001. Red Española de Terapias Avanzadas
“Financiado por el instituto de Salud Carlos III- Unión Europea –
NextGenerationEU - Plan de Recuperación Transformación y Resiliencia.



Colabora



Place: Hotel 525, calle Rio Borines, 58. Los Alcázares (Murcia – Spain)

Duration: 25 hours.

Max enrollment: 200 students.

Price online: 100 €.

Price face-to-face (lunch included): 160 €.

REGISTRATION RULES

Please complete the Registration Form at the official website: ----->
www.um.es/web/cursosdeextension Payment Methods: Credit Card (Website) Cash
– only in person: Download the Payment form.

Fill in the form and return it with your payment to Universidad Internacional del Mar. Banks: Banco Sabadell, CaixaBank, Cajamar and Banco Santander.

Once payment is made you will be enrolled in the course. Students must be enrolled and have a regular attendance to obtain the diploma or its equivalent.

CREDIT RECOGNITION

This course enables you to obtain elective credits at the Universidad of Murcia, in accordance with the University's academic regulations. Students registered at other universities must provide the Credit recognition requirements for transfer of credit toward their degree program at their home university (certificate, diploma, program...).

OBJECTIVES

In-Depth Analysis of Advanced Therapies: Examine the various types of advanced therapies and the underlying biological mechanisms that drive their therapeutic potential.

Cutting-Edge Advances: Explore recent breakthroughs in gene therapy, CAR-T cell immunotherapy, somatic cell therapies, and the manufacturing processes for advanced cell therapies that comply with regulatory standards. Gain insights into key regulatory principles and emerging technologies shaping future developments.

Preclinical and Clinical Progress: Present and discuss the current status of preclinical research and clinical trials involving advanced therapies, with a focus on their potential to treat and cure diseases.

TARGET GROUP

This course aims to disseminate knowledge on Advanced Therapies—including gene therapy, somatic cell therapy, and tissue engineering—and their therapeutic potential, with a particular focus on current applications in genetic disorders, neoplastic diseases, and regenerative medicine.

The program is designed to:

Provide an overview of the latest clinical applications of advanced therapies.

Foster scientific dialogue among leading basic and clinical researchers specializing in advanced therapies. Highlight both the achievements and challenges in this rapidly evolving field of medical science.

Wednesday 2.

Introduction to advanced therapies.

The Spanish Network of Advanced Therapies. Update of translational research achievements.

09:00-09:30 h. Opening Session.

Hon. Mr. José Luján.

Rector of the University of Murcia. Murcia, Spain.

Morning Session.

09:30-10:30 h. Advanced Therapies: principles and definitions. New Medicinal Products to Cure Diseases. The Spanish Network of Advanced Therapies: A collaborative research model.

Prof. Agustín Zapata and **Prof. José M^a Moraleda.**

Ricors TeraV Coordinators. ISCIII.

Advances in Gene Therapy:

Chairs:

Juan Bueren.

Biomedical Innovation Unit. CIEMAT. Spain.

Francisco Martín Molina.

GENYO. University of Granada. Spain.

10:30-11:00 h. Introduction to Gene Editing: Results for Gene Therapy Applications.

Francisco Javier Molina Estévez. GENYO. Faculty of Medicine. University of Granada. Spain.

11:00-11:30 h. Break.

11:30-12:00 h. Results of Gene Therapy in Hematological Diseases.

Prof. Juan Bueren.

Head Division of Hematopoiesis and Gene Therapy. CIEMAT. University of Madrid, Spain.

12:00-12:30 h. Results of Gene Therapy in Metabolic Diseases.

Prof. Gloria González-Aseguinolaza.

Head of the Gene Therapy Program at CIMA Coordinator of advanced therapies at IdiSNA. University of Navarra. Pamplona. Spain.

12:30-13:00 h. Oncolytic Virotherapy: Basic Concepts and Medical Applications.

Prof. Ramón Alemany.

Head Cancer immunotherapy division. Institut Català d'Oncologia – IDIBELL. Barcelona. Spain of the Unit for Cell & Gene Therapies.

13:00-13:30 h. Results of Clinical Trials Using Oncolytic virus for Pediatric Diseases.

Prof. Marta Alonso.

Director of the Advanced Therapies Laboratory for pediatric solid tumors. CIMA. University of Navarra. Pamplona. Spain

13:30-14:00 h. Results of Clinical Trials Using Allogeneic Mesenchymal Cells and Oncolytic Adenovirus.

Prof. Javier García-Castro.

Director of the Unit for Cell Biotechnology. Institute of Health Carlos III. Majadahonda. Spain.

14:00-15:30 h. Lunch.

Afternoon Session.

Advances in Somatic Cell Therapy and Tissue Engineering.

Chairs:

Prof. Fermín Sánchez-Guijo.

Professor of Hematology. University of Salamanca, Spain.

Prof. Damián García-Olmo.

Professor of Surgery. Autonomous University of Madrid. Spain.

15:30-16:00 h. Principles of Mesenchymal stromal cell (MSC) therapy. Applications in Critical Limb Ischemia.

Prof. Mariano García Arranz.

Senior Research. Fundación Jimenez Diaz. Autonomous University of Madrid. Madrid, Spain

16:00-16:30 h. MSC Therapy for Arthritis.

Prof. José Lamo de Espinosa.

Professor of Orthopedics, University of Navarra. Spain.

16:30-17:00. Tissue Engineering in the treatment of Skin Diseases.

Prof. Alvaro Meana.

University of Oviedo. Oviedo. Spain

17:00- 17:30 h. Outcomes of the MSC-Fucosylated Clinical Trial in Osteoporosis Treatment.

Prof. Ana María García Hernández.

Director of CPU. University Hospital Virgen de la Arrixaca. IMIB-Arrixaca. Murcia. Spain.

17:30-18:00 h. Alofisel: The first Cell Therapy Approved by EMA: Lessons for the Future.

Prof. Damián García-Olmo.

Professor of Surgery. Autonomous University of Madrid. Spain.

Thursday 3.

The Spanish Network of Advanced Therapies: Update on Translational Research Achievements.

Morning Session.

Advances in Antitumor Immunotherapy: Chimeric Antigen Receptor Cell Results.

Chairs:

Prof. Manel Juan.

Head Immunology Dpt. Hospital Clinic of Barcelona. University of Barcelona. Spain.

Prof. Felipe Prósper.

Professor of Hematology. University of Navarra. Spain.

09:00-9:30 h. Principles of CAR-T Cells: Results of Academically Developed CAR T-Cells

(Ari 0001, Ari 0002 and Beyond).

Prof. Manel Juan.

Head Immunology Dpt. Hospital Clinic of Barcelona. University of Barcelona, Spain.

09:30-10:00h. Transpo-CAR: A New Technology for Safer and More Effective CARs.

Prof. Felipe Prósper.

Professor of Hematology. University of Navarra. CIMA. Spain.

10:00-10:30 h. Academic CART-Cells in T-Cell Acute Lymphoblastic Leukemia.

Prof. Pablo Menéndez.

Research Professor. ICREA. José Carreras Research Institute. University of Barcelona. Spain.

10:30-11:00 h. Clinical Results of CAR T-Cells in Non-Hodgkin's Lymphoma.

Prof. Anna Sureda.

President EBMT. Head Hematology Dpt. ICO. Barcelona, Spain

11:00-11:30 h. Break.

11:30-12:00 h. Innovative CAR T-Cells in Multiple Myeloma Treatment.

Prof. José Antonio Pérez Simón.

Professor of Medicine. University of Sevilla. Hospital Virgen del Rocio. Sevilla, Spain.

12:00-12:30 h. Academic CART30 for the Treatment of Hodgkin Lymphoma : Role of Memory T cells.

Prof Javier Briones.

Head Hematology and Gene Therapy Dpt. Hospital Sant Pau. Autonomous University of Barcelona. Spain.

12:30-13:00 h. CAR-NK: Principles and Manufacture.

Prof. Cristina Eguizabal.

Coordinator of Advanced Therapies Unit at Basque Center for Blood Transfusion and Human Tissues-Osakidetza. Group Leader of Cell Therapy, Stem Cells and Tissues Group at Biobizkaia Health Research Institute, Bilbao, Spain.

13:00-13:30 h. The Patient Perspective on CAR-T Cell Therapy: Insights and Opportunities for Improvement.

Prof. Natacha Bolaños.

Patient association. Lymphoma coalition. Spain.

13:30-15:30 h. Lunch.

Afternoon Session.

15:30-16:00 h. 'Armed' CAR and T cell engagers: New Immunotherapies in Malignancies.

Prof. Joaquín Martínez.

Professor of Medicine. Autonomous University of Madrid. Hospital 12 Octubre, Madrid, Spain.

16:00-16:30 h. Viral Production for Gene Therapy and Advanced Therapies.

Prof. Unai Perpiñá.

Stem Cell and Regenerative Medicine Research Unit. Dept of Biomedicine. Barcelona. Spain.

16:30-17:00 h. The Spanish Model of Point-of-Care Manufacturing for Academic CAR Therapies.

Prof. Eulàlia Olesti.

Department of Clinical Pharmacology. Hospital Clinic de Barcelona, Barcelona Spain.

17:00-17:30 h. Invited Conference: Artificial Intelligence and Advanced Therapies in clinical medicine: A win-win approach.

Prof. José Manuel García.

Full Professor of Computer Engineering. Head of the Parallel Computing Architecture Research Group. University of Murcia. Murcia. Spain.

Friday 4.

The Spanish Network of Advanced Therapies: Update on Translational Research Achievements.

Morning Session.

Advances in Technology Innovations and Translation.

Chairs:

Prof. Anna Sureda. President EBMT.

Head Hematology Dpt. ICO. Barcelona, Spain.

Prof. Salvador Martínez.

Institute of Neurosciences. University Miguel Hernandez. Elche.

09:00-9:30 h. Results of Innovative Therapies Based on Cell and Tissue Donation.

Prof. Joaquim Vives.

Head of Cellular Therapy Service—Banc de Sang i Teixits (Barcelona). Spain.

09:30-10:00 h. Innovative SoHO for Advanced Therapies: Dental Pulp MSCs and pericytes.

Prof. Salvador Martínez.

Professor of Human Anatomy and Embryology. University Miguel Hernandez-CSIC. Elche. Spain.

10:00-10:30 h. Organoids as a New Tool for ATMP Research: Results in Disease Modeling.

Prof. Elena Garreta.

Professor of Research. Bio-engineering Institute of Catalonia (IBEC). Barcelona. Spain.

10:30-11:00 h. Break

11:00-11:30 h. Genetically Engineered Animal Models for Novel Therapeutic Approaches.

Prof. Joaquín Gadea. Professor in Physiology and Reproductive Biology. University of Murcia. Murcia. Spain.

11:30-12:00 h. Results from the TeraV GMP Platform: Potency and Quality Testing.

Prof. María Eugenia Fernández-Santos.

PhD. Technical Director. Cell Production Unit. Gregorio Marañón University Hospital. Madrid, Spain.

12:00-12:30 h. ATMP Manufacturing Education Programs: Results of the Radytta Initiative.

Prof. Gloria Carmona.

Radytta. Andalusian Advanced therapies initiative. Health and Progress Foundation. Sevilla.

12:30-13:00 h. Hospital Exemption and Key Regulatory Points for Academic Manufacturing.

Prof. Cristina Avendaño.

Coordinator. Regulatory Committee. Spanish Network of Advanced Therapies.

13:00-13:30 h. Keynote Speech: International Cooperation of TeraV to Facilitate Access to ATMPs in Latin America: The Mexico Experience.

Prof. Alejandro Madrigal.

Professor of Haematology, UCL Cancer Institute. Honorary Consultant, Royal Free NHS Trust. London, UK. External Advisor TeraV.

13:30-14:30 h. Scientific discussion and Concluding Remarks.

Prof. José M.^a Moraleda.

Emeritus Professor. University of Murcia. Spain. TeraV Coordinator.

Prof. Agustín Zapata.

Emeritus Professor. Complutense University of Madrid. TeraV Coordinator.

14:30-15:30 h. Lunch.

15:30-16:00 h. Closing ceremony.

Los gastos realizados por el personal incluido en el programa de esta actividad, en referencia a comidas o servicios de restauración, tendrán la consideración de gastos de reuniones y conferencias (art. 79 bis IREPUM).